StockNews.AI
XRAY
StockNews.AI
173 days

Dentsply Sirona Reports Fourth Quarter and Full Year 2024 Results, Provides Full Year 2025 Outlook

1. FY24 net sales decreased 4.3%, driven by organic sales fall. 2. GAAP net loss for FY24 totaled $910 million, significantly higher than 2023. 3. Fourth quarter saw a 10.6% drop in net sales from last year. 4. 2025 outlook projects net sales between $3.50 billion and $3.60 billion. 5. Significant goodwill impairments noted in Q4, impacting overall financial health.

Earnings
-12.49%Current Return
VS
-1.72%S&P 500
$18.8102/27 06:04 AM EDTEvent Start
$16.4602/28 01:03 PM EDTLatest Updated
38m saved
Insight
Article

FAQ

Why Bearish?

Dentsply Sirona's substantial loss and declining sales reflect a struggling business, reminiscent of historical downturns.

How important is it?

The reported losses and decreased sales directly impact XRAY's financial outlook and investor confidence.

Why Short Term?

Immediate negative financial results will likely affect investor sentiment and stock price soon.

Related Companies

BDXHSIC
FY24 net sales of $3,793 million decreased (4.3%), organic sales decreased (3.5%) including a (1.2%) Byte sales impactFY24 GAAP net loss of ($910) million or ($4.48) per share, adjusted EPS of $1.67Q4 net sales of $905 million decreased (10.6%), organic sales decreased (10.7%) including a (6.0%) Byte sales impactQ4 GAAP net loss of ($430) million or ($2.16) per share, adjusted EPS of $0.26FY25 outlook: net sales in the range of $3.50 billion to $3.60 billion with organic sales down (4.0%) to (2.0%); adjusted EPS of $1.80 to $2.00(1) CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced its financial results for the fourth quarter and full year of 2024. Full year 2024 net sales of $3,793 million decreased (4.3%) (organic sales decreased (3.5%) including a (1.2%) Byte sales impact), compared to the full year of 2023. Net loss was ($910) million, or ($4.48) per share, compared to net loss of ($132) million, or ($0.62) per share for the full year of 2023. Non-cash charges for the impairment of goodwill and other intangible assets were ($870) million net of tax, or ($4.27) per share in 2024, and ($302) million net of tax, or ($1.42) per share in 2023. Adjusted earnings per diluted share were $1.67, compared to $1.83 in 2023. Fourth quarter net sales of $905 million decreased (10.6%) (organic sales decreased (10.7%) including a (6.1%) Byte sales impact) compared to the fourth quarter of 2023. Net loss was ($430) million, or ($2.16) per diluted share, compared to net income of $67 million, or $0.32 per share in the fourth quarter of 2023. Non-cash charges for the impairment of goodwill and other intangible assets were ($370) million net of tax, or ($1.86) per share in the fourth quarter of 2024, versus no impairment charges in the fourth quarter of 2023. Adjusted earnings per diluted share were $0.26 compared to $0.44 in the fourth quarter of 2023. A reconciliation of Non-GAAP measures (including organic sales, adjusted EBITDA and margin, adjusted EPS, adjusted free cash flow conversion, and segment adjusted operating income) to GAAP measures is provided below. "In 2024 we made meaningful progress on our transformational agenda to strengthen our foundation and position the company for long-term success. While we were pleased to see improvement in several areas of the business, Byte, persistent macro pressures and competitive dynamics negatively impacted Q4 and 2024 full year results. Improvements in Q4 included a return to growth in Europe and imaging globally, as well as continued growth of Wellspect Healthcare and SureSmile," said Simon Campion, President and Chief Executive Officer. "In 2025, we anticipate the external environment to remain broadly unchanged, with our transformational initiatives driving EBITDA margin expansion and adjusted EPS growth. As we look forward, we believe our differentiated portfolio, robust innovation pipeline, and increased focus on customer experience and organizational efficiency, position us to capitalize on strategic opportunities and create value for our stakeholders." ________________________ (1) As explained below under the heading Full Year 2025 Outlook, the Company does not provide a forward-looking estimate of earnings on a GAAP basis due to unavailability of certain information. Q4 24 and FY 24 Summary Results (GAAP) (in millions, except per share amount and percentages) Q4 24 Q4 23 YoY FY 24 FY 23 YoYNet Sales $905 $1,012 (10.6%) $3,793 $3,965 (4.3%)Gross Profit $446 $522 (14.7%) $1,958 $2,086 (6.1%)Gross Margin 49.2% 51.6%   51.6% 52.6%  Net (Loss) Income Attributable to Dentsply Sirona ($430) $67 NM ($910) ($132) NMDiluted (Loss) Earnings Per Share [1] ($2.16) $0.32 NM ($4.48) ($0.62) NM Q4 24 and FY 24 Summary Results (Non-GAAP)[2] (in millions, except per share amount and percentages) Q4 24 Q4 23 YoY FY 24 FY 23 YoYNet Sales $905 $1,012 (10.6%) $3,793 $3,965 (4.3%)Organic Sales Growth %     (10.7%)     (3.5%)Adjusted EBITDA $128 $173 (25.9%) $631 $691 (8.8%)Adjusted EBITDA Margin 14.2% 17.1%   16.6% 17.4%  Adjusted EPS $0.26 $0.44 (41.3%) $1.67 $1.83 (8.4%) NM - not meaningfulPercentages are based on actual values and may not reconcile due to rounding.[1] Because the Company recorded net losses in the fourth quarter of 2024, no potential dilutive common shares were used in the computation of diluted loss per common share as the effect would have been antidilutive.[2] Organic sales growth, adjusted EBITDA, and adjusted EPS are Non-GAAP financial measures which exclude certain items. Please refer to "Non-GAAP Financial Measures" below for a description of these measures and to the tables at the end of this release for a reconciliation between GAAP and Non-GAAP measures.Percentages are based on actual values and may not recalculate due to rounding. Q4 24 and FY 24 Segment Results   Net Sales Growth % Organic Sales Growth %  Q4 24FY 24 Q4 24FY 24       Connected Technology Solutions (8.3%)(9.2%) (8.2%)(8.2%)Essential Dental Solutions (3.5%)(0.9%) (3.4%)(0.1%)Orthodontic and Implant Solutions (28.6%)(6.5%) (28.7%)(5.5%)Wellspect Healthcare 8.6%5.9% 6.7%5.8%Total (10.6%)(4.3%) (10.7%)(3.5%) Q4 24 and FY 24 Geographic Results   Net Sales Growth % Organic Sales Growth %  Q4 24FY 24 Q4 24FY 24       United States (29.8%)(6.2%) (29.9%)(6.2%)Europe 2.8%(2.1%) 1.8%(2.2%)Rest of World (3.4%)(5.1%) (2.0%)(1.5%)Total (10.6%)(4.3%) (10.7%)(3.5%) Cash Flow and Liquidity Operating cash flow in the fourth quarter of 2024 was $87 million, compared to $160 million in the fourth quarter of 2023, primarily due to unfavorable timing of working capital adjustments. Full year 2024 operating cash flow was $461 million, as compared to $377 million in the prior year, primarily driven by improved management of inventory levels and favorable timing of cash collections. In the fourth quarter, the Company paid $31 million in dividends resulting in a total of $376 million returned to shareholders through dividends and share repurchases in 2024. The Company had $272 million of cash and cash equivalents as of December 31, 2024. Goodwill and Intangible Asset Impairments In the fourth quarter of 2024, the Company recorded non-cash charges for the impairment of goodwill and other intangible assets of ($370) million net of tax within the Orthodontic and Implant Solutions and Connected Technology Solutions segments. These impairments were driven by weakened demand and competitive pressures in implants and equipment, and a full write-off of the Byte trademark based on a determination that the trademark will not be used in the future aligners operating model. Quarterly Cash Dividend On February 26, 2025, the Company's Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on April 11, 2025 to holders of record as of March 28, 2025. Full Year 2025 Outlook The 2025 outlook includes anticipated net sales in the range of $3.50 billion to $3.60 billion, down (4.0%) to (2.0%) on an organic basis, which includes a (2%) Byte sales impact. Adjusted EPS is expected to be in the range of $1.80 to $2.00. Other 2025 outlook assumptions are included in the fourth quarter 2024 earnings presentation posted on the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. The Company does not provide forward-looking estimates of earnings on a GAAP basis as certain information, which may include, but is not limited to, restructuring charges, transformation-related costs, impairment charges, certain tax adjustments, and other significant items, is not available without unreasonable effort and cannot be reasonably estimated. The exact amounts of these charges or credits are not currently determinable but may be significant. Conference Call/Webcast InformationDentsply Sirona’s management team will host an investor conference call and live webcast on February 27, 2025, at 8:30 am ET. The live webcast of the investor conference call and a presentation related to the call will be available on the Investors section of the Company’s website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at https://register.vevent.com/register/BIf5e9c0837d394c3abe9009d8a418b3e6. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call. About Dentsply SironaDentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide, high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona’s headquarters is located in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products. Contact Information:Investors:Andrea DaleyVice President, Investor Relations+1-704-591-8631InvestorRelations@dentsplysirona.com Press:Marion Par-WeixlbergerVice President, Public Relations & Corporate Communications+43 676 848414588marion.par-weixlberger@dentsplysirona.com Forward-Looking Statements and Associated Risks All statements in this Press Release that do not directly and exclusively relate to historical facts constitute “forward-looking statements.” Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part I, Item 1A, “Risk Factors” of the Company's most recent Annual Report on Form 10-K, and any updating information or other factors which may be described in the Company’s other filings with the Securities and Exchange Commission (the “SEC”). No assurance can be given that any expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Press Release or to reflect the occurrence of unanticipated events. Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company’s SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.  DENTSPLY SIRONA INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In millions, except per share amounts and percentages)(unaudited) Three Months Ended Year Ended December 31, December 31,  2024   2023   2024   2023         Net sales$905  $1,012  $3,793  $3,965 Cost of products sold 459   490   1,835   1,879         Gross profit 446   522   1,958   2,086         Selling, general, and administrative expenses 401   409   1,605   1,613 Research and development expenses 42   43   165   184 Goodwill and intangible asset impairments 504   —   1,014   307 Restructuring costs 8   (3)  53   67         Operating (loss) income (509)  73   (879)  (85)        Other income and expenses:       Interest expense, net 16   20   69   81 Other (income) expense, net (2)  (4)  (12)  9         (Loss) income before income taxes (523)  57   (936)  (175)Benefit from income taxes (95)  (15)  (26)  (43)        Net (loss) income (428)  72   (910)  (132)        Less: Net income attributable to noncontrolling interests 2   5   —   —         Net (loss) income attributable to Dentsply Sirona$(430) $67  $(910) $(132)        Net (loss) income per common share attributable to Dentsply Sirona:       Basic$(2.16) $0.32  $(4.48) $(0.62)Diluted$(2.16) $0.32  $(4.48) $(0.62)        Weighted average common shares outstanding:       Basic 198.8   210.0   203.2   212.0 Diluted 198.8   210.9   203.2   212.0   DENTSPLY SIRONA INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(In millions)(unaudited)     December 31, 2024 December 31, 2023    Assets   Current Assets:   Cash and cash equivalents$272  $334 Accounts and notes receivable-trade, net 556   695 Inventories, net 564   624 Prepaid expenses and other current assets 354   320 Total Current Assets 1,746   1,973     Property, plant and equipment, net 766   800 Operating lease right-of-use assets, net 136   178 Identifiable intangible assets, net 1,207   1,705 Goodwill, net 1,597   2,438 Other noncurrent assets 301   276 Total Assets$5,753  $7,370     Liabilities and Equity   Current Liabilities:   Accounts payable$241  $305 Accrued liabilities 754   749 Income taxes payable 45   49 Notes payable and current portion of long-term debt 549   322 Total Current Liabilities 1,589   1,425     Long-term debt 1,586   1,796 Operating lease liabilities 91   125 Deferred income taxes 129   228 Other noncurrent liabilities 415   502 Total Liabilities 3,810   4,076     Total Equity 1,943   3,294     Total Liabilities and Equity$5,753  $7,370   DENTSPLY SIRONA INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(In millions) (unaudited)  Year Ended December 31,  2024   2023 Cash flows from operating activities:       Net loss$(910) $(132)    Adjustments to reconcile net loss to net cash provided by operating activities:   Depreciation 133   132 Amortization of intangible assets 216   211 Goodwill impairment 773   291 Intangible asset impairment 241   16 Deferred income taxes (136)  (130)Stock-based compensation expense 39   46 Equity in earnings from unconsolidated affiliates —   4 Other non-cash (income) expense (9)  (2)Loss (gain) on disposal of property, plant and equipment 19   (3)Changes in operating assets and liabilities:   Accounts and notes receivable-trade, net 104   (58)Inventories, net 17   6 Prepaid expenses and other current assets 38   (58)Other noncurrent assets (5)  4 Accounts payable (30)  14 Accrued liabilities (39)  17 Income taxes 38   (11)Other noncurrent liabilities (28)  30 Net cash provided by operating activities$461  $377     Cash flows from investing activities:       Cash received on sale of non-strategic businesses or product lines —   13 Capital expenditures (180)  (149)Cash received on derivative contracts 1   39 Cash paid on derivative contracts (12)  — Other investing activities, net (6)  8 Net cash used in investing activities$(197) $(89)    Cash flows from financing activities:       Proceeds from long-term borrowings 1   — Repayments on long-term borrowings (88)  (7)Net borrowings on short-term borrowings 177   126 Cash paid for treasury stock (250)  (300)Cash dividends paid (126)  (116)Other financing activities, net (16)  (10)Net cash used in financing activities$(302) $(307)    Effect of exchange rate changes on cash and cash equivalents (24)  (12)    Net decrease in cash and cash equivalents (62)  (31)Cash and cash equivalents at beginning of period 334   365 Cash and cash equivalents at end of period$272  $334     Supplemental disclosures of cash flow information:   Interest paid, net of amounts capitalized$91  $97 Income taxes paid, net of refunds 74   177 Non-cash investing activities:   Change in accounts payable related to capital expenditures$8  $6  Non-GAAP Financial Measures In addition to results determined in accordance with U.S. generally accepted accounting principles (“US GAAP”), the Company provides certain measures in this press release, described below, which are not calculated in accordance with US GAAP and therefore represent Non-GAAP measures. These Non-GAAP measures are used by the Company to measure its performance and may differ from those used by other companies. These Non-GAAP measures should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP. Management believes that these Non-GAAP measures are helpful as they provide a measure of the results of operations, and are frequently used by investors and analysts to evaluate the Company’s performance exclusive of certain items that impact the comparability of results from period to period, and which may not be indicative of past or future performance of the Company. Organic Sales The Company defines "organic sales" as the reported net sales adjusted for: (1) net sales from acquired businesses recorded prior to the first anniversary of the acquisition; (2) net sales attributable to disposed businesses or discontinued product lines in both the current and prior year periods; and (3) the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's foreign currency exchange rates. Adjusted Operating Income and Margin Adjusted operating income is computed by excluding the following items from operating income (loss) as reported in accordance with US GAAP: (1) Business combination-related costs and fair value adjustments. These adjustments include costs related to consummating and integrating acquired businesses, as well as net gains and losses related to disposed businesses. In addition, this category includes the post-acquisition roll-off of fair value adjustments recorded related to business combinations, except for amortization expense of purchased intangible assets noted below. Although the Company is regularly engaged in activities to find and act on opportunities for strategic growth and enhancement of product offerings, the costs associated with these activities may vary significantly between periods based on the timing, size and complexity of acquisitions and as such may not be indicative of past and future performance of the Company. (2) Restructuring-related charges and other costs. These adjustments include costs related to the implementation of restructuring initiatives, including but not limited to, severance costs, facility closure costs, and lease and contract termination costs, as well as related professional service costs associated with these restructuring initiatives and global transformation activity. The Company is continually seeking to take actions that could enhance its efficiency; consequently, restructuring charges may recur but are subject to significant fluctuations from period to period due to the varying levels of restructuring activity, and as such may not be indicative of past and future performance of the Company. Other costs include gains and losses on the sale of property, charges related to legal settlements, executive separation costs, write-offs of inventory as a result of product rationalization, and changes in accounting principles recorded within the period. This category also includes costs related to investigations and associated remediation activities, which primarily include legal, accounting and other professional service fees, as well as turnover and other employee-related costs. (3) Goodwill and intangible asset impairments. These adjustments include charges related to goodwill and intangible asset impairments. (4) Amortization of purchased intangible assets. This adjustment excludes the periodic amortization expense related to purchased intangible assets, which are recorded at fair value. Although these costs contribute to revenue generation and will recur in future periods, their amounts are significantly impacted by the timing and size of acquisitions, and as such may not be indicative of the future performance of the Company. (5) Fair value and credit risk adjustments. These adjustments include the non-cash mark-to-market changes in fair value associated with pension assets and obligations, the credit risk component of hedging instruments, and equity-method investments. Although these adjustments are recurring in nature, they are subject to significant fluctuations from period to period due to changes in the underlying assumptions and market conditions. The non-service component of pension expense is a recurring item, however it is subject to significant fluctuations from period to period due to changes in actuarial assumptions, interest rates, plan changes, settlements, curtailments, and other changes in facts and circumstances. As such, these items may not be indicative of past and future performance of the Company. Adjusted operating margin is calculated by dividing adjusted operating income by net sales. Adjusted Gross Profit Adjusted gross profit is computed by excluding from gross profit the impact of any of the above adjustments that affect either sales or cost of sales. Adjusted Net Income (Loss) Adjusted net income (loss) consists of net income (loss) as reported in accordance with US GAAP, adjusted to exclude the items identified above, as well as the related income tax impacts of those items. Additionally, net income is adjusted for other tax-related adjustments such as: discrete adjustments to valuation allowances and other uncertain tax positions, final settlement of income tax audits, discrete tax items resulting from the implementation of restructuring initiatives and the windfall or shortfall relating to exercise of employee share-based compensation, any difference between the interim and annual effective tax rate, and adjustments relating to prior periods. These adjustments are irregular in timing, and the variability in amounts may not be indicative of past and future performance of the Company and therefore are excluded for comparability purposes. Adjusted EBITDA and Margin In addition to the adjustments described above in arriving at adjusted net income, adjusted EBITDA is computed by further excluding any remaining interest expense, net, income tax expense, depreciation and amortization. Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by net sales. Adjusted Earnings (Loss) Per Diluted Share Adjusted earnings (loss) per diluted share (adjusted EPS) is computed by dividing adjusted earnings (loss) attributable to Dentsply Sirona shareholders by the diluted weighted average number of common shares outstanding. Adjusted Free Cash Flow and Conversion The Company defines adjusted free cash flow as net cash provided by operating activities minus capital expenditures during the same period, and adjusted free cash flow conversion is defined as adjusted free cash flow divided by adjusted net income (loss). Management believes this Non-GAAP measure is important for use in evaluating the Company’s financial performance as it measures our ability to efficiently generate cash from our business operations relative to earnings. It should be considered in addition to, rather than as a substitute for, net income (loss) as a measure of our performance or net cash provided by operating activities as a measure of our liquidity. DENTSPLY SIRONA INC. AND SUBSIDIARIES(In millions, except percentages)(unaudited) A reconciliation of reported net sales to organic sales by geographic region is as follows:   Three Months Ended December 31, 2024 Q4 2024 Change Three Months Ended December 31, 2023(in millions, except percentages) U.S.EuropeROWTotal U.S.EuropeROWTotal U.S.EuropeROWTotal                Net sales $259$408$238$905 (29.8%)2.8%(3.4%)(10.6%) $368$397$247$1,012Foreign exchange impact      0.1%1.0%(1.4%)0.1%     Organic sales      (29.9%)1.8%(2.0%)(10.7%)      Percentages are based on actual values and may not recalculate due to rounding.   Year Ended December 31, 2024 2024 Change Year Ended December 31, 2023(in millions, except percentages) U.S.EuropeROWTotal U.S.EuropeROWTotal U.S.EuropeROWTotal                Net sales $1,348$1,518$927$3,793 (6.2%)(2.1%)(5.1%)(4.3%) $1,437$1,550$978$3,965Foreign exchange impact      —%0.1%(3.6%)(0.8%)     Organic sales      (6.2%)(2.2%)(1.5%)(3.5%)      Percentages are based on actual values and may not recalculate due to rounding. A reconciliation of reported net sales to organic sales by segment is as follows:   Three Months Ended December 31, 2024 Q4 2024 Change Three Months Ended December 31, 2023(in millions, except percentages) Connected Technology SolutionsEssential Dental SolutionsOrthodontic and Implant SolutionsWellspect HealthcareTotal Connected Technology SolutionsEssential Dental SolutionsOrthodontic and Implant SolutionsWellspect HealthcareTotal Connected Technology SolutionsEssential Dental SolutionsOrthodontic and Implant SolutionsWellspect HealthcareTotal                   Net sales $293$346$185$81$905 (8.3%)(3.5%)(28.6%)8.6%(10.6%) $319$358$259$76$1,012Foreign exchange impact       (0.1%)(0.1%)0.1%1.9%0.1%      Organic sales       (8.2%)(3.4%)(28.7%)6.7%(10.7%)       Percentages are based on actual values and may not recalculate due to rounding.   Year Ended December 31, 2024 2024 Change Year Ended December 31, 2023(in millions, except percentages) Connected Technology SolutionsEssential Dental SolutionsOrthodontic and Implant SolutionsWellspect HealthcareTotal Connected Technology SolutionsEssential Dental SolutionsOrthodontic and Implant SolutionsWellspect HealthcareTotal Connected Technology SolutionsEssential Dental SolutionsOrthodontic and Implant SolutionsWellspect HealthcareTotal                   Net sales $1,062$1,454$973$304$3,793 (9.2%)(0.9%)(6.5%)5.9%(4.3%) $1,169$1,468$1,040$288$3,965Foreign exchange impact       (1.0%)(0.8%)(1.0%)0.1%(0.8%)      Organic sales       (8.2%)(0.1%)(5.5%)5.8%(3.5%)       Percentages are based on actual values and may not recalculate due to rounding. DENTSPLY SIRONA INC. AND SUBSIDIARIES(In millions, except percentages)(unaudited) The Company’s segment adjusted operating income for the three months and year ended December 31, 2024 and 2023 was as follows:   Three Months Ended December 31, Year Ended December 31,(in millions)  2024   2023   2024   2023          Connected Technology Solutions $49  $47  $70  $101 Essential Dental Solutions  107   113   479   478 Orthodontic and Implant Solutions  (28)  27   80   156 Wellspect Healthcare  25   22   98   87 Segment adjusted operating income  153   209   727   822          Reconciling items expense (income):        Unallocated corporate costs (a)  93   84   320   319 Interest expense, net  16   20   69   81 Other (income) expense, net  (2)  (4)  (12)  9 Goodwill and intangible asset impairments  504   —   1,014   307 Restructuring and other costs  8   (3)  53   67 Amortization of intangibles  54   52   216   211 Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations  3   3   3   3 Loss before income taxes $(523) $57  $(936) $(175) (a) Unallocated corporate costs consist of general corporate expenses including corporate headcount costs, depreciation and amortization, unallocated professional service fees, and other operating costs which are not assigned to a specific segment. DENTSPLY SIRONA INC. AND SUBSIDIARIES(In millions, except per share amounts and percentages)(unaudited) For the three months ended December 31, 2024, a reconciliation of selected items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP items is as follows: (in millions, except percentages and per share data) Gross Profit Operating(Loss) Income Net (Loss)IncomeAttributable toDentsply Sirona (a) Diluted EPSGAAP $446  $(509) $(430) $(2.16)Non-GAAP Adjustments:        Amortization of Purchased Intangible Assets  30   54   40   0.20 Restructuring-Related Charges and Other Costs  1   45   36   0.18 Goodwill and Intangible Asset Impairments  —   504   370   1.86 Business Combination Related Costs and Fair Value Adjustments  —   2   2   — Income Tax-Related Adjustments  —   —   33   0.18 Adjusted Non-GAAP $477  $96  $51  $0.26 GAAP Margin    (56.2%)    Adjusted Non-GAAP Margin    10.5%             Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share  198.8 Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share  199.3 (a) The total tax expense on the Non-GAAP adjustments totals $124 million which is inclusive of the $33 million income tax-related adjustment above.   Percentages are based on actual values and may not reconcile due to rounding. DENTSPLY SIRONA INC. AND SUBSIDIARIES(In millions, except per share amounts and percentages)(unaudited) For the three months ended December 31, 2023, a reconciliation of selected items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP items is as follows: (in millions, except percentages and per share data) Gross Profit OperatingIncome Net IncomeAttributable toDentsply Sirona (a) Diluted EPSGAAP $522  $73  $67  $0.32 Non-GAAP Adjustments:        Amortization of Purchased Intangible Assets  30   52   37   0.18 Restructuring-Related Charges and Other Costs  6   16   14   0.06 Business Combination-Related Costs and Fair Value Adjustments  —   2   3   0.01 Income Tax-Related Adjustments  —   —   (28)  (0.13)Adjusted Non-GAAP $558  $143  $93  $0.44 GAAP Margin    7.2%    Adjusted Non-GAAP Margin    14.1%             Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share  210.0 Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share  210.9 (a) The tax expense on the Non-GAAP adjustments totals $44 million, which is inclusive of the $(28) million income tax-related adjustment above.   Percentages are based on actual values and may not reconcile due to rounding. DENTSPLY SIRONA INC. AND SUBSIDIARIES(In millions, except per share amounts and percentages)(unaudited) For the year ended December 31, 2024, a reconciliation of selected items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP items is as follows: (in millions, except percentages and per share data) Gross Profit Operating(Loss) Income Net (Loss)IncomeAttributable toDentsply Sirona (a) Diluted EPSGAAP $1,958  $(879) $(910) $(4.48)Non-GAAP Adjustments:        Amortization of Purchased Intangible Assets  122   216   159   0.78 Restructuring-Related Charges and Other Costs  6   136   106   0.53 Goodwill and Intangible Asset Impairments  —   1,014   870   4.27 Business Combination-Related Costs and Fair Value Adjustments  2   4   3   0.01 Fair Value and Credit Risk Adjustments  —   —   2   0.01 Income Tax-Related Adjustments  —   —   111   0.55 Adjusted Non-GAAP $2,088  $491  $341  $1.67 GAAP Margin    (23.2%)    Adjusted Non-GAAP Margin    12.9%             Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share  203.2 Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share  203.8 (a) The total tax expense on the Non-GAAP adjustments totals $121 million, which is inclusive of the $111 million income tax-related adjustment above.   Percentages are based on actual values and may not reconcile due to rounding. DENTSPLY SIRONA INC. AND SUBSIDIARIES(In millions, except per share amounts and percentages)(unaudited) For the year ended December 31, 2023, a reconciliation of selected items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP items is as follows: (in millions, except percentages and per share data) Gross Profit Operating(Loss) Income Net (Loss)IncomeAttributable toDentsply Sirona (a) Diluted EPSGAAP $2,086  $(85) $(132) $(0.62)Non-GAAP Adjustments:        Amortization of Purchased Intangible Assets  121   211   154   0.73 Restructuring-Related Charges and Other Costs  18   123   95   0.44 Goodwill and Intangible Asset Impairments  —   307   302   1.42 Business Combination-Related Costs and Fair Value Adjustments  2   15   14   0.07 Fair Value and Credit Risk Adjustments  —   —   —   — Income Tax-Related Adjustments  —   —   (44)  (0.21)Adjusted Non-GAAP $2,227  $571  $389  $1.83 GAAP Margin    (2.1%)    Adjusted Non-GAAP Margin    14.4%             Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share  212.0 Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share  213.1 (a) The total tax expense on the Non-GAAP adjustments totals $139 million, which is inclusive of the $(44) million income tax-related adjustment above.   Percentages are based on actual values and may not reconcile due to rounding. DENTSPLY SIRONA INC. AND SUBSIDIARIES(In millions, except per share amounts and percentages)(unaudited) A reconciliation of reported net (loss) income attributable to Dentsply Sirona to adjusted EBITDA and margin for the three months ended December 31, 2024 and 2023 is as follows:   Three Months Ended December 31,(in millions)  2024   2023      Net (loss) income attributable to Dentsply Sirona $(430) $67 Interest expense, net  16   20 Income tax benefit  (95)  (15)Depreciation(1)  31   32 Amortization of purchased intangible assets  54   52 Restructuring-related charges and other costs  45   16 Goodwill and intangible asset impairments  504   — Business combination-related costs and fair value adjustments  2   2 Fair value and credit risk adjustments  1   — Rounding  —   (1)Adjusted EBITDA(2) $128  $173      Net sales $905  $1,012 Adjusted EBITDA margin  14.2%  17.1% (1) Excludes those depreciation-related amounts which were included as part of the business combination-related adjustments and Restructuring-related charges and other costs.(2) Adjusted EBITDA for Q4 2023 has been updated to reflect the reclassification of $1 million in certain gains from hedging instruments from Interest expense to Other expense (income) in order to conform with current year presentation.Percentages are based on actual values and may not reconcile due to rounding. A reconciliation of reported loss attributable to Dentsply Sirona to adjusted EBITDA and margin for the year ended December 31, 2024 and 2023 is as follows:   Year Ended December 31,(in millions)  2024   2023      Net loss attributable to Dentsply Sirona $(910) $(132)Interest expense, net  69   81 Income tax benefit  (26)  (43)Depreciation(1)  126   126 Amortization of purchased intangible assets  216   211 Restructuring-related charges and other costs  136   123 Goodwill and intangible asset impairments  1,014   307 Business combination-related costs and fair value adjustments  4   18 Fair value and credit risk adjustments  2   — Adjusted EBITDA(2) $631  $691      Net sales $3,793  $3,965 Adjusted EBITDA margin  16.6%  17.4% (1) Excludes those depreciation-related amounts which were included as part of the business combination-related adjustments and Restructuring-related charges and other costs.(2) Adjusted EBITDA for 2023 has been updated to reflect the reclassification of $1 million in certain gains from hedging instruments from Interest expense to Other expense (income) in order to conform with current year presentation.Percentages are based on actual values and may not reconcile due to rounding. DENTSPLY SIRONA INC. AND SUBSIDIARIES(In millions, except per share amounts and percentages)(unaudited) A reconciliation of adjusted free cash flow conversion for the three months ended December 31, 2024 and 2023 is as follows:   Three Months Ended December 31,(in millions, except percentages)  2024   2023      Net cash provided by operating activities $87  $160 Capital expenditures  (51)  (40)Adjusted free cash flow  36   120      Adjusted net income $52  $93 Adjusted free cash flow conversion  72%  128% Percentages are based on actual values and may not reconcile due to rounding. A reconciliation of adjusted free cash flow conversion for the year ended December 31, 2024 and 2023 is as follows:   Year Ended December 31,(in millions, except percentages)  2024   2023      Net cash provided by operating activities $461  $377 Capital expenditures  (180)  (149)Adjusted free cash flow  281   228      Adjusted net income $341  $389 Adjusted free cash flow conversion  83%  58% Percentages are based on actual values and may not reconcile due to rounding.

Related News